Loxo Oncology, Inc. (NASDAQ:LOXO) Director David P. Bonita sold 250,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $82.50, for a total transaction of $20,625,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Loxo Oncology, Inc. (NASDAQ LOXO) opened at $82.71 on Wednesday. Loxo Oncology, Inc. has a 1 year low of $25.25 and a 1 year high of $95.92.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc grew its position in Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 284 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 419 shares in the last quarter. Wells Fargo & Company MN grew its position in Loxo Oncology by 3.8% in the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock valued at $1,291,000 after acquiring an additional 592 shares in the last quarter. New York State Common Retirement Fund grew its position in Loxo Oncology by 2.9% in the third quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock valued at $2,312,000 after acquiring an additional 700 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in Loxo Oncology by 3.1% in the third quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 1,094 shares in the last quarter.

A number of research analysts have recently commented on LOXO shares. JMP Securities downgraded shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price objective (up previously from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Citigroup dropped their price objective on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. Ifs Securities raised shares of Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research report on Tuesday, November 14th. Finally, William Blair began coverage on shares of Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $90.57.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/13/loxo-oncology-inc-loxo-director-david-p-bonita-sells-250000-shares.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.